Viome, an investee company through Milltrust’s partnership with Cerracap Ventures, is focused on disrupting healthcare by “making illness optional”. The Viome test is a breakthrough microbiome bacteria, epigenetics, epigenome and epigenomics technology.
Milltrust has a block of USD 5 million at a 20 percent discount to the last raise. Contact us for more information.
Categories: News
Tags: Healthcare Science Technology viome